ReviewThe p53 and Mdm2 families in cancer
Introduction
The p53 tumor suppressor gene encodes a sequence-specific transcription factor whose activity is either disabled or attenuated in the vast majority of human cancers 1., 2., 3., 4., 5.. p53 inactivation is often achieved through mutations affecting the p53 locus directly. In other cases, p53 functionality is compromised through excessive activity of its major negative regulator, Mdm2, as well as of the Mdm2-related protein MdmX.
Several years ago, two p53-related genes were identified, and were eventually dubbed p63 and p73, respectively. Although both proteins bear significant similarity to p53, the physiological functions of each member of the p53 family appear to be rather distinct [6]. Thus, p53-null mice exhibit only relatively limited developmental defects, particularly affecting neural tube closure and spermatogenesis. In contrast, mice lacking p63 display severe developmental defects in epithelial cell differentiation and die shortly after birth, whereas p73-deficient mice suffer from a variety of other developmental aberrations, affecting primarily the nervous system and the respiratory tract [6]. The differences among the individual p53 family members also extend to the effect of their ablation on cancer development. Mice null for p53 are highly susceptible to cancer with a relatively early onset, and heterozygotes retaining only a single wild-type (wt) p53 allele are also cancer prone, albeit with a later onset and usually contingent upon somatic loss of the remaining p53 allele. In contrast, neither loss of p73 nor viable loss of a p63 allele seem to predispose mice to cancer. Thus, at least in these mouse models, neither p63 nor p73 behaves as a tumor suppressor. Nevertheless, numerous studies utilizing human tumor material as well as cultured cells have indicated non-random relationships between altered expression of p63 and p73 and cancer. Attempts to establish unequivocally the relevance of p63 and p73 to cancer are complicated by the fact that, unlike p53, these proteins exist in multiple forms as a result of alternative splicing and usage of multiple transcription start sites. In fact, it is now becoming clear that these different variants often exert opposing effects on cell fate and cell behavior. Thus, the transactivation competent (TA) variants of p63 and p73 can activate to varying degrees many canonical p53 target genes, and may in some circumstances double for p53 in its anti-proliferative action. In contrast, variants lacking the transactivation domain (ΔN forms) actually antagonize TA family members, including p53 itself. Consequently, their hyperactivation may in fact exert oncogenic rather than tumor-suppressor effects.
The Mdm2 and MdmX proteins 7., 8., 9. maintain yet another level of regulation on the p53 family. Mdm2 possesses E3 ubiquitin ligase activity towards p53. Through its ability to ubiquitinate p53 and target if for proteasomal degradation, Mdm2 plays a key role in retaining p53 at very low concentrations under non-stressed conditions. At the same time, the Mdm2 gene is a positive transcriptional target of p53, whose expression is often elevated subsequent to induction of p53 activity. This defines a negative feedback loop wherein p53 upregulates Mdm2, whereas Mdm2 downregulates p53. This loop can be viewed as a regulatory module, into which a plethora of incoming signals feed and thereby modulate p53 levels and activity in accordance with intracellular and extracellular cues. Unlike Mdm2, its ‘cousin’ MdmX does not drive the destruction of p53. Hence, the relevance of MdmX as a physiological regulator of p53 function has been questioned in the past. However, MdmX is also emerging now as part of the intricate network that controls the cellular activity of p53.
In this review, we focus on some of the advances made during the past year towards elucidating the complex interplay between Mdm2, MdmX and the p53 family members, with particular emphasis on cancer-related issues. New papers addressing these proteins keep appearing at an enormous rate, with >4700 publications on p53 published in 2000 alone. Hence, it is impossible to cover comprehensively all the recent literature in such a short review. In many instances review articles, rather than primary reports, are cited. We apologize to all authors whose important work has not been cited.p53: optimizer of cell fate?
Recent advances in the cloning of p53 orthologs from Drosophila and Caenorhabditis elegans have highlighted the evolutionary conservation of p53 functions. As in higher organisms, these orthologs are required for apoptosis following ionizing irradiation 10., 11., 12••.. Likewise, the requirement for p53 in assuring proper meiotic chromosome segregation in C. elegans [12••] is reminiscent of the role of p53 in mouse spermatogenesis [13].
The p53-dependent apoptotic response is a well-documented anti-cancer mechanism 3., 14., as are p53-dependent growth arrest and DNA repair. The antiproliferative effects of p53 are called into action in response to a variety of stress signals, many of which are implicated in neoplastic processes [1]. A recently reported novel inducer of the p53 response is massive genomic DNA demethylation, as is caused by inactivation of the DNA-methyltransferase gene Dnmt1 [15]; this response culminates in apoptosis, eliminating cells whose gene expression patterns have been distorted via aberrant demethylation. Similarly, p53-dependent replicative senescence also serves to curtail the proliferation of potentially cancer-prone cells. p53 can also address oncogenic stress more directly, by counteracting the oncogenic forces that drive neoplastic cell behavior. For instance, p53 activation accelerates degradation of β-catenin, whose oncogenic action contributes to a variety of epithelial tumors 16., 17., 18..
The molecular mechanisms through which p53 elicits apoptosis have been explored extensively [3]. The past year has yielded an impressive array of new pro-apoptotic transcriptional targets of p53. These include the gene encoding apoptotic protease-activating factor-1 (Apaf-1) 19•., 20•., 21•., the Bcl-2-binding protein PUMA 22•., 23•., the death-domain protein Pidd [24], the tumor-suppressor phosphatase PTEN [25•] and p53DINP1 [26]. Other genes that can modulate cell fate, shown to be targets of p53, include HB-EGF, which activates the MAPK pathway [27] and c-Ha-Ras [28]. Interestingly, the apoptotic activity of p53 is modulated in a selective manner by LKB1, a serine/threonine kinase the malfunction of which underlies the Peutz–Jegher syndrome (PJS); this disease involves the formation of multiple intestinal polyps, some eventually progressing to malignancy [29•]. Defective p53-dependent apoptosis may underlie the high tumor susceptibility of PJS patients.
Whereas pivotal pro-apoptotic functions of p53 are being unraveled, it is noteworthy that p53 may also exert anti-apoptotic effects under certain circumstances. In some cases, functional p53 may even interfere with cell killing by chemotherapy [30]. Interestingly, p53 dictates the resistance of non-transformed cells to parvoviruses, which kill efficiently tumor cells lacking functional p53 31., 32.. p53 may, thus, adjust the cell-fate decisions to the particular signals that drive the p53 response. A remarkable case in point is the contribution of p53 to the extended longevity of C. elegans under stressful conditions [12••]. Hence, the role of p53 as ‘optimizer of cell fate’ most probably extends well beyond the mere prevention of cancer.
Section snippets
p63 and p73: tumor suppressors?
Whereas the TA forms of p63 and p73 resemble p53 in many ways, including the ability to transactivate common target genes and induce apoptosis when overexpressed, the ΔN forms lacking the transactivation domain (TAD) antagonize p53 and its family members. It therefore appears plausible that ΔN p63 and p73 may exert oncogenic effects. Indeed, TA p63 expression is lost in various carcinomas, whereas expression of ΔN p63 is not altered significantly relative to normal cells 33., 34., 35.. In other
The complex Mdm2 family portrait
Maintaining p53 at low levels through rapid turnover, under most physiological conditions, enables cell survival and proper organismal development 48., 49., 50., 51.. This is achieved largely through the ability of Mdm2 to target p53 for ubiquitin-dependent proteasomal degradation, although non-proteasomal mechanisms for p53 degradation may also play a significant role under certain circumstances 52., 53.. Mdm2 displays an E3 ubiquitin ligase activity towards p53 [54]. However, the role of Mdm2
The central p53–Mdm2 module
The p53–Mdm2 autoregulatory module serves as a node into which many p53-modulating signals converge (Fig. 1). The balance of these various signals eventually dictates cell fate.
Work performed over several years has identified a series of residues within the amino terminal domain of p53, the stress-induced phosphorylation of which renders p53 more transcriptionally active and less susceptible to inhibition by Mdm2 2., 50.. In addition, p53 becomes acetylated in response to stress, by p300/CBP as
Conclusions
Early studies revealed that p53 is mutated directly in about half of all human tumors, making it the most frequent target for mutations in human cancer. As the intricate p53-regulatory network is being unraveled, it is becoming clear that in the vast majority of the remaining 50% of tumors that retain wt p53 expression, the function of that protein is also severely compromised. This can occur through augmented expression and activity of its negative regulators, Mdm2 and MdmX, as well as through
Acknowledgements
Work of the authors laboratory is supported in part by grant RO1 CA40099 from the National Institutes of Health (USA), The USA–Israel Binational Science Foundation, the Kadoorie Charitable Foundations, the Co-operation Program in Cancer Research of the German Cancer Research Center (DKFZ) and Israel's Ministry of Science, the Robert Bosch Foundation (Germany) and Yad Abraham Center for Cancer Diagnostics and Therapy.
References and recommended reading
Papers of particular interest, published within the annual period of review,have been highlighted as:
• of special interest
•• of outstanding interest
References (88)
p53: death star
Cell
(2000)- et al.
Regulation of p53 function
Exp Cell Res
(2001) - et al.
MDM2: life without p53
Trends Genet
(2001) - et al.
MDM2 — master regulator of the p53 tumor suppressor protein
Gene
(2000) - et al.
Drosophila p53 is a structural and functional homolog of the tumor suppressor p53
Cell
(2000) - et al.
Drosophila p53 binds a damage response element at the reaper locus
Cell
(2000) - et al.
p53 and apoptosis
Semin Cancer Biol
(1998) - et al.
Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein
Mol Cell
(2001) - et al.
Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses
Mol Cell
(2001) - et al.
PUMA induces the rapid apoptosis of colorectal cancer cells
Mol Cell
(2001)
i>PUMA, a novel proapoptotic gene, is induced by p53
Mol Cell
Regulation of PTEN Transcription by p53
Mol Cell
p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis
Mol Cell
The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death
Mol Cell
Physical and functional interaction between p53 mutants and different isoforms of p73
J Biol Chem
p63 and p73: old members of a new family
Biochim Biophys Acta
Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia
Ann Oncol
The ARF/p53 pathway
Curr Opin Genet Dev
Oncogenes induce and activate endogenous p73 protein
J Biol Chem
Regulation of the p53 tumor suppressor protein
J Biol Chem
MDM2 function
Biochim Biophys Acta
Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes
Blood
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
FEBS Lett
Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53
Exp Cell Res
Mdm2 mutant defective in binding p300 promotes ubiquitination but not degradation of p53: evidence for the role of p300 in integrating ubiquitination and proteolysis
J Biol Chem
Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein
J Biol Chem
Stabilization of the MDM2 oncoprotein by mutant p53
J Biol Chem
P53 and PML: new partners in tumor suppression
Trends Cell Biol
Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF
Cell
JunD protects cells from p53-dependent senescence and apoptosis
Mol Cell
Cyclin a-CDK phosphorylation regulates MDM2 protein interactions
J Biol Chem
Surfing the p53 network
Nature
The p53 pathway
J Pathol
The ins and outs of p53
Nat Cell Biol
p63 and p73: p53 mimics, menaces and more
Nat Rev Mol Cell Biol
Mdm2: the ups and downs
Mol Med
C. elegans p53: role in apoptosis, meiosis, and stress resistance
Science
Mice with reduced levels of p53 protein exhibit the testicular giant- cell degenerative syndrome
Proc Natl Acad Sci USA
Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation
Nat Genet
Down-regulation of beta-catenin by activated p53
Mol Cell Biol
Apaf-1 is a transcriptional target for E2F and p53
Nat Cell Biol
DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1
Oncogene
APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis
Cancer Res
Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis
Nat Genet
Cited by (244)
Natural compounds as a potential modifier of stem cells renewal: Comparative analysis
2023, European Journal of PharmacologyNovel microtubule inhibitor SQ overcomes multidrug resistance in MCF-7/ADR cells by inhibiting BCRP function and mediating apoptosis
2022, Toxicology and Applied PharmacologyApoptotic effect of chromanone derivative, hyrtiosone A from marine demosponge Hyrtios erectus in hepatocellular carcinoma HepG2 cells
2021, Bioorganic ChemistryCitation Excerpt :The MDM2 is tightly regulated by p53 through the promotion of MDM2 transcription in an auto-inhibitory feedback loop [10]. The activation of p53 pathway by attenuating MDM2 has been considered as a prominent therapeutic strategy for cancer treatment [10]. On the other hand, the p27 protein is frequently get inactivated in hepatocellular carcinoma (HCC), and was considered to predict the pathophysiology related to liver cancer.
Hepatocellular carcinoma (HepG2/C3A) cell-based 3D model for genotoxicity testing of chemicals
2021, Science of the Total EnvironmentBaicalin mediated regulation of key signaling pathways in cancer
2021, Pharmacological Research